

CLAIM SET AS AMENDED

1.(Currently Amended) ~~Solid~~ A solid pharmaceutical preparation comprising at least one at least partially charged active substance, ~~characterized in that~~ wherein the active substance is present in form of a nanosol in which the active substance is bonded to an oppositely charged chitosan derivative.

2.(Currently Amended) ~~Solid~~ The solid pharmaceutical preparation according to Claim 1, ~~characterized in that~~ wherein the active substance possesses a positive charge and is bonded to a zwitterionic, acidic chitosan derivative.

3. (Currently Amended) ~~Solid~~ The solid pharmaceutical preparation according to Claim 1, ~~characterized in that~~ wherein the active substance possesses a negative charge and is bonded to a basic chitosan derivative.

4. (Currently Amended) ~~Solid~~ The solid pharmaceutical preparation according to claim 1, ~~characterized in that~~ wherein the active substance and the chitosan derivative are present in the nanosol in almost isoionic state.

5. (Currently Amended) ~~Solid~~ The solid pharmaceutical preparation according to claim 1, ~~characterized in that~~ wherein the active substance is present in the nanosol in colloidal or in nanoparticulate form.

6. (Currently Amended) ~~Solid~~ The solid pharmaceutical preparation according to claim 1,
~~characterized in that~~ wherein the active substance is poorly soluble.

7. (Currently Amended) ~~Solid~~ The solid pharmaceutical preparation according to claim 1,
~~characterized in that~~ wherein it contains a further polymeric carrier substance apart from the
chitosan derivative.

8. (Currently Amended) ~~Use of a~~ The pharmaceutical preparation according to claim 1,
wherein the preparation is used for the production of a medicinal product.

9. (Currently Amended) ~~Use of a~~ The pharmaceutical preparation according to ~~any one~~
~~of Claims 1 to 7~~ claim 1, wherein the preparation is used for the production of a medicinal
product for peroral application.

10. (Currently Amended) ~~Use of a~~ The pharmaceutical preparation according to claim 8,
wherein the preparation is used for the production of a medicinal product that is administered as a
powder, granulate, tablet or capsule.

11. (Currently Amended) ~~Use of a~~ The pharmaceutical preparation according to claim 8,
wherein the ~~for the production of~~ a medicinal product which, for the purpose of administration,
is dissolved or redispersed in a liquid.

12. (Currently Amended) ~~Use of a~~ The pharmaceutical preparation according to claim 8,
wherein the for the production of a medicinal product having ~~has~~ controlled active substance
release.

13. (Currently Amended) ~~Use of a~~ The pharmaceutical preparation according to claim 1,
wherein the preparation is used for the production of a diagnostic agent.

14. (Currently Amended) ~~Process for the production of a pharmaceutical preparation
according to claim 1, characterized in that~~ A process for the production of a solid pharmaceutical
preparation comprising at least one at least partially charged active substance, which active
substances is present in the form of a nanosol in which the active substance is bonded to an
oppositely charged chitosan derivative, which comprises:

- a) selecting a chitosan derivative ~~is selected~~ according to the type and relative number of its charged groups and in coordination with the type and relative number of the charged groups of the active substance such that at a certain pH value an isoionic state or charge equalization between active substance and carrier can be achieved in the preparation,
- b) preparing an aqueous sol containing the active substance ~~is prepared~~ from the chitosan derivative,
- c) adjusting the pH value of the aqueous sol ~~is adjusted~~ such that an isoionic state results, possibly with colloidal or nano-scale active substance particles precipitating, and
- d) drying the thus-adjusted aqueous sol ~~is dried~~.

15.(New) The process according to claim 14, wherein said active substance possesses a positive charge and is bonded to a zwitterionic, acidic chitosan derivative.

16.(New) The process according to claim 14, wherein said active substance possesses a negative charge and is bonded to a basic chitosan derivative.

17.(New) The process according to claim 14, wherein said active substance is poorly soluble.

18.(New) The process according to claim 14, wherein a further polymeric carrier substance is used apart from the chitosan derivative.